Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 | NEJM
New England Journal of Medicine
Original Article from The New England Journal of Medicine — Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
NEJM du jour : #Tocilizumab #COVID19 suite et fin?
Pas d'effet significatif dans un nième essai contrôlé Bloquer complètement une seule cytokine dans une tempête moins efficace que d'agir sur tous les mécanismes de l'inflammation avec #dexaméthasone
Another negative trial for an expensive drug that has been used extensively in India during this pandemic. Almost every second opinion I give involves a patient who has received at least two doses. Note that the potential for harm hasn’t been ruled out.
Tocilizumab has no benefit in #COVID_19 Double blind randomized trial. Another non evidence-based commonly used treatment bites the dust.
Tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19- "Efficacy of Tocilizumab in Patients Hospitalized with Covid-19"
Dr Gaetan Burgio, MD, PhD.
Another randomized controlled clinical trial with Tocilizumab (IL-6 blocker) vs placebo for 243 hospitalized moderate #COVID19 patients with pneumonia -> No difference in intubation and mortality. Now pretty clear idea Toci is not efficacious for COVID19
More negative results in trials testing antiviral/antiInflamatory therapies for COVID19 disease Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 | NEJM